{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:32:00Z","timestamp":1790703120299,"version":"4.1.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T00:00:00Z","timestamp":1383091200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s40265-013-0133-0","type":"journal-article","created":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T10:15:14Z","timestamp":1383041714000},"page":"1863-1888","source":"Crossref","is-referenced-by-count":79,"title":["Therapeutic Options for Visceral Leishmaniasis"],"prefix":"10.1007","volume":"73","author":[{"given":"Bego\u00f1a","family":"Monge-Maillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"L\u00f3pez-V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,30]]},"reference":[{"key":"133_CR1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.idc.2012.03.005","volume":"26","author":"J Griensven van","year":"2012","unstructured":"van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am. 2012;26:309\u201322.","journal-title":"Infect Dis Clin North Am"},{"key":"133_CR2","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.","journal-title":"PLoS One"},{"key":"133_CR3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14656566.2013.755515","volume":"14","author":"S Sundar","year":"2013","unstructured":"Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother. 2013;14:53\u201363.","journal-title":"Expert Opin Pharmacother"},{"key":"133_CR4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","volume":"61","author":"J Alvar","year":"2006","unstructured":"Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol. 2006;61:223\u201374.","journal-title":"Adv Parasitol"},{"key":"133_CR5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"SL Croft","year":"2006","unstructured":"Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111\u201326.","journal-title":"Clin Microbiol Rev"},{"key":"133_CR6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/CMR.00061-07","volume":"21","author":"J Alvar","year":"2008","unstructured":"Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10\u00a0years. Clin Microbiol Rev. 2008;21:334\u201359.","journal-title":"Clin Microbiol Rev"},{"key":"133_CR7","unstructured":"World Health Organization. WHO technical report series. Control of the leishmaniases. Report of a meeting of the WHO expert committee on the control of leishmaniases, Geneva, 2010. http:\/\/whqlibdoc.who.int\/trs\/WHO_TRS_949_eng.pdf ."},{"key":"133_CR8","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1086\/656735","volume":"51","author":"AR Khan","year":"2010","unstructured":"Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51:1147\u201356.","journal-title":"Clin Infect Dis"},{"key":"133_CR9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/319366","volume":"32","author":"MA Kish","year":"2001","unstructured":"Kish MA. Infectious Diseases Society of America. Guide to development of practice guidelines. Clin Infect Dis. 2001;32:851\u20134.","journal-title":"Clin Infect Dis"},{"key":"133_CR10","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/jac\/37.5.1042","volume":"37","author":"D Torrus","year":"1996","unstructured":"Torrus D, Boix V, Massa B, Portilla J, Perez-Mateo M. Fluconazole plus allopurinol in treatment of visceral leishmaniasis. J Antimicrob Chemother. 1996;37:1042\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"133_CR11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0035-9203(81)90198-X","volume":"75","author":"PA Kager","year":"1981","unstructured":"Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyerly WH. Allopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1981;75:556\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR12","first-page":"611","volume":"147","author":"R Ragusa","year":"1993","unstructured":"Ragusa R, Di Cataldo A, Samperi P, Schiliro G. Treatment of visceral leishmaniasis with meglumine and allopurinol. Am J Dis Child. 1993;147:611\u20132.","journal-title":"Am J Dis Child"},{"key":"133_CR13","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/0140-6736(90)93358-V","volume":"336","author":"S Sundar","year":"1990","unstructured":"Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis. Lancet. 1990;336:1582\u20133.","journal-title":"Lancet"},{"key":"133_CR14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/infdis\/166.1.215","volume":"166","author":"JP Wali","year":"1992","unstructured":"Wali JP, Aggarwal P, Gupta U, Saluja S, Singh S. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar. J Infect Dis. 1992;166:215\u20136.","journal-title":"J Infect Dis"},{"key":"133_CR15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/clind\/16.3.397","volume":"16","author":"MA Halim","year":"1993","unstructured":"Halim MA, Alfurayh O, Kalin ME, Dammas S, al-Eisa A, Damanhouri G. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin Infect Dis. 1993;16:397\u20139.","journal-title":"Clin Infect Dis"},{"key":"133_CR16","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1093\/ndt\/14.12.2941","volume":"14","author":"M Hueso","year":"1999","unstructured":"Hueso M, Bover J, Seron D, et al. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol. Nephrol Dial Transpl. 1999;14:2941\u20133.","journal-title":"Nephrol Dial Transpl"},{"issue":"Suppl 1","key":"133_CR17","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.trstmh.2006.02.011","volume":"100","author":"S Sundar","year":"2006","unstructured":"Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2006;100(Suppl 1):S26\u201333.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00034989958096","volume":"93","author":"S Sundar","year":"1999","unstructured":"Sundar S, Gupta LB, Makharia MK, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol. 1999;93:589\u201397.","journal-title":"Ann Trop Med Parasitol"},{"key":"133_CR19","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/318122","volume":"31","author":"S Sundar","year":"2000","unstructured":"Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis. 2000;31:1110\u20133.","journal-title":"Clin Infect Dis"},{"key":"133_CR20","first-page":"434","volume":"22","author":"S Sundar","year":"2003","unstructured":"Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J. 2003;22:434\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"133_CR21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/380638","volume":"38","author":"SK Bhattacharya","year":"2004","unstructured":"Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis. 2004;38:217\u201321.","journal-title":"Clin Infect Dis"},{"key":"133_CR22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/BF02763048","volume":"73","author":"UK Singh","year":"2006","unstructured":"Singh UK, Prasad R, Mishra OP, Jayswal BP. Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study. Indian J Pediatr. 2006;73:1077\u201380.","journal-title":"Indian J Pediatr"},{"key":"133_CR23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4269\/ajtmh.2011.10-0661","volume":"85","author":"M Rahman","year":"2011","unstructured":"Rahman M, Ahmed BN, Faiz MA, et al. Phase\u00a0IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg. 2011;85:66\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"133_CR24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","volume":"55","author":"S Sundar","year":"2012","unstructured":"Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis. 2012;55:543\u201350.","journal-title":"Clin Infect Dis"},{"key":"133_CR25","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1128\/AAC.47.8.2397-2403.2003","volume":"47","author":"FJ Perez-Victoria","year":"2003","unstructured":"Perez-Victoria FJ, Castanys S, Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother. 2003;47:2397\u2013403.","journal-title":"Antimicrob Agents Chemother"},{"key":"133_CR26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2006.04.001","volume":"9","author":"FJ Perez-Victoria","year":"2006","unstructured":"Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, et al. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat. 2006;9:26\u201339.","journal-title":"Drug Resist Updat"},{"key":"133_CR27","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","volume":"56","author":"S Rijal","year":"2013","unstructured":"Rijal S, Ostyn B, Uranw S, et al. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis. 2013;56:1530\u20138.","journal-title":"Clin Infect Dis"},{"key":"133_CR28","doi-asserted-by":"crossref","unstructured":"Prajapati VK, Sharma S, Rai M, et\u00a0al. In\u00a0vitro susceptibility of Leishmania donovani to miltefosine in indian visceral leishmaniasis. Am J Trop Med Hyg. 2013;89:750\u20134.","DOI":"10.4269\/ajtmh.13-0096"},{"key":"133_CR29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/505217","volume":"43","author":"K Ritmeijer","year":"2006","unstructured":"Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006;43:357\u201364.","journal-title":"Clin Infect Dis"},{"key":"133_CR30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00001432-200212000-00007","volume":"15","author":"S Sundar","year":"2002","unstructured":"Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis. 2002;15:593\u20138.","journal-title":"Curr Opin Infect Dis"},{"key":"133_CR31","first-page":"848","volume-title":"The leishmaniasis in biology and medicine","author":"AD Bryceson","year":"1987","unstructured":"Bryceson AD. Therapy in man. In: Peters W, Killick-Kendrich R, editors. The leishmaniasis in biology and medicine. London: Academics Press; 1987. p. 848\u2013903."},{"key":"133_CR32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(83)92588-6","volume":"1","author":"GM Anabwani","year":"1983","unstructured":"Anabwani GM, Ngira JA, Dimiti G, Bryceson AD. Comparison of two dosage schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. Lancet. 1983;1:210\u20133.","journal-title":"Lancet"},{"key":"133_CR33","first-page":"103","volume":"93","author":"CP Thakur","year":"1991","unstructured":"Thakur CP, Kumar M, Pandey AK. Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate. Indian J Med Res. 1991;93:103\u201310.","journal-title":"Indian J Med Res"},{"key":"133_CR34","unstructured":"World Health Organization. Report of the informal meeting on the chemotherapy of visceral leishmaniasis, WHO. Geneva, 1982."},{"key":"133_CR35","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/bmj.296.6636.1557","volume":"296","author":"CP Thakur","year":"1988","unstructured":"Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed). 1988;296:1557\u201361.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"133_CR36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1179\/000349804225003154","volume":"98","author":"CP Thakur","year":"2004","unstructured":"Thakur CP, Narayan S. A comparative evaluation of amphotericin\u00a0B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol. 2004;98:129\u201338.","journal-title":"Ann Trop Med Parasitol"},{"key":"133_CR37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4269\/ajtmh.1992.46.296","volume":"46","author":"BL Herwaldt","year":"1992","unstructured":"Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992;46:296\u2013306.","journal-title":"Am J Trop Med Hyg"},{"key":"133_CR38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/infdis\/168.3.715","volume":"168","author":"J Seaman","year":"1993","unstructured":"Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis. 1993;168:715\u201320.","journal-title":"J Infect Dis"},{"key":"133_CR39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1365-3156.2000.00555.x","volume":"5","author":"H Veeken","year":"2000","unstructured":"Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health. 2000;5:312\u20137.","journal-title":"Trop Med Int Health"},{"key":"133_CR40","first-page":"388","volume":"79","author":"E Moore","year":"2001","unstructured":"Moore E, O\u2019Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ. 2001;79:388\u201393.","journal-title":"Bull World Health Organ"},{"key":"133_CR41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/136485908X252142","volume":"102","author":"Y Mueller","year":"2008","unstructured":"Mueller Y, Nguimfack A, Cavailler P, et al. Safety and effectiveness of amphotericin\u00a0B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann Trop Med Parasitol. 2008;102:11\u20139.","journal-title":"Ann Trop Med Parasitol"},{"key":"133_CR42","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.trstmh.2010.07.007","volume":"104","author":"W Hailu","year":"2010","unstructured":"Hailu W, Weldegebreal T, Hurissa Z, et al. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Trans R Soc Trop Med Hyg. 2010;104:706\u201312.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR43","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/j.1365-3156.2008.02144.x","volume":"13","author":"L Gradoni","year":"2008","unstructured":"Gradoni L, Soteriadou K, Louzir H, et al. Drug regimens for visceral leishmaniasis in mediterranean countries. Trop Med Int Health. 2008;13:1272\u20136.","journal-title":"Trop Med Int Health"},{"key":"133_CR44","first-page":"191","volume":"73","author":"L Gradoni","year":"1995","unstructured":"Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ. 1995;73:191\u20137.","journal-title":"Bull World Health Organ"},{"key":"133_CR45","doi-asserted-by":"crossref","first-page":"e814","DOI":"10.1371\/journal.pntd.0000814","volume":"4","author":"R Petrela","year":"2010","unstructured":"Petrela R, Kuneshka L, Foto E, Zavalani F, Gradoni L. Pediatric visceral leishmaniasis in Albania: a retrospective analysis of 1,210 consecutive hospitalized patients (1995\u20132009). PLoS Negl Trop Dis. 2010;4:e814.","journal-title":"PLoS Negl Trop Dis"},{"key":"133_CR46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/00365540410020451","volume":"36","author":"SM Jeronimo","year":"2004","unstructured":"Jeronimo SM, Duggal P, Braz RF, et al. An emerging peri-urban pattern of infection with Leishmania chagasi, the protozoan causing visceral leishmaniasis in northeast Brazil. Scand J Infect Dis. 2004;36:443\u20139.","journal-title":"Scand J Infect Dis"},{"key":"133_CR47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1590\/S0037-86822002000600014","volume":"35","author":"MA Santos","year":"2002","unstructured":"Santos MA, Marques RC, Farias CA, et al. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis. Rev Soc Bras Med Trop. 2002;35:629\u201333.","journal-title":"Rev Soc Bras Med Trop"},{"key":"133_CR48","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Leishmaniasis en las Americas. Recomedaciones para el tratamiento. Washington, DC OPS, 2013. http:\/\/www.paho.org\/hq\/index.php?option=com_docman&task=doc_view&gid=22226&Itemid= ."},{"key":"133_CR49","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/archderm.1960.01580040145026","volume":"82","author":"SA Sampaio","year":"1960","unstructured":"Sampaio SA, Godoy JT, Paiva L, Dillon NL, da Lacaz CS. The treatment of American (mucocutaneous) leishmaniasis with amphotericin\u00a0B. Arch Dermatol. 1960;82:627\u201335.","journal-title":"Arch Dermatol"},{"key":"133_CR50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0035-9203(63)90183-4","volume":"57","author":"A Prata","year":"1963","unstructured":"Prata A. Treatment of kala-azar with amphotericin\u00a0B. Trans R Soc Trop Med Hyg. 1963;57:266\u20138.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR51","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4269\/ajtmh.1995.52.536","volume":"52","author":"TK Jha","year":"1995","unstructured":"Jha TK, Giri YN, Singh TK, Jha S. Use of amphotericin\u00a0B in drug-resistant cases of visceral leishmaniasis in North Bihar, India. Am J Trop Med Hyg. 1995;52:536\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"133_CR52","first-page":"57","volume":"6","author":"CP Thakur","year":"1993","unstructured":"Thakur CP, Sinha GP, Pandey AK, Barat D, Sinha PK. Amphotericin\u00a0B in resistant kala-azar in Bihar. Natl Med J India. 1993;6:57\u201360.","journal-title":"Natl Med J India"},{"key":"133_CR53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/tropej\/fmp132","volume":"56","author":"UK Singh","year":"2010","unstructured":"Singh UK, Prasad R, Jaiswal BP, Singh PK, Thakur CP. Amphotericin\u00a0B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial. J Trop Pediatr. 2010;56:321\u20134.","journal-title":"J Trop Pediatr"},{"key":"133_CR54","first-page":"14","volume":"113","author":"CP Thakur","year":"2001","unstructured":"Thakur CP, Ahmed S. Observations on amphotericin\u00a0B treatment of kala-azar given in a rural set up in Bihar, India. Indian J Med Res. 2001;113:14\u20138.","journal-title":"Indian J Med Res"},{"key":"133_CR55","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0140-6736(94)90406-5","volume":"344","author":"M Mishra","year":"1994","unstructured":"Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet. 1994;344:1599\u2013600.","journal-title":"Lancet"},{"key":"133_CR56","first-page":"931","volume":"72","author":"CP Thakur","year":"1994","unstructured":"Thakur CP, Sinha GP, Pandey AK, Barat D, Singh RK. Daily versus alternate-day regimen of amphotericin\u00a0B in the treatment of kala-azar: a randomized comparison. Bull World Health Organ. 1994;72:931\u20136.","journal-title":"Bull World Health Organ"},{"key":"133_CR57","first-page":"282","volume":"100","author":"A Toumi","year":"2007","unstructured":"Toumi A, Kilani B, Ammari L, et al. Demographic, clinical and therapeutic features of adult visceral leishmaniasis at the Rabta Hospital in Tunis (Tunisia) from 1983 to 2002. Bull Soc Pathol Exot. 2007;100:282\u20136.","journal-title":"Bull Soc Pathol Exot"},{"key":"133_CR58","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","volume":"38","author":"S Sundar","year":"2004","unstructured":"Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin\u00a0B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004;38:377\u201383.","journal-title":"Clin Infect Dis"},{"key":"133_CR59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-8579(00)00312-5","volume":"17","author":"CP Thakur","year":"2001","unstructured":"Thakur CP. A single high dose treatment of kala-azar with ambisome (amphotericin\u00a0B lipid complex): a pilot study. Int J Antimicrob Agents. 2001;17:67\u201370.","journal-title":"Int J Antimicrob Agents"},{"key":"133_CR60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4269\/ajtmh.2002.66.143","volume":"66","author":"S Sundar","year":"2002","unstructured":"Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin\u00a0B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg. 2002;66:143\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"133_CR61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4269\/ajtmh.2010.10-0156","volume":"83","author":"PK Sinha","year":"2010","unstructured":"Sinha PK, Roddy P, Palma PP, et al. Effectiveness and safety of liposomal amphotericin\u00a0B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg. 2010;83:357\u201364.","journal-title":"Am J Trop Med Hyg"},{"key":"133_CR62","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0035-9203(96)90271-0","volume":"90","author":"CP Thakur","year":"1996","unstructured":"Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin\u00a0B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg. 1996;90:319\u201322.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.323.7310.419","volume":"323","author":"S Sundar","year":"2001","unstructured":"Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin\u00a0B: randomised trial. BMJ. 2001;323:419\u201322.","journal-title":"BMJ"},{"key":"133_CR64","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/377542","volume":"37","author":"S Sundar","year":"2003","unstructured":"Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin\u00a0B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis. 2003;37:800\u20134.","journal-title":"Clin Infect Dis"},{"key":"133_CR65","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","volume":"362","author":"S Sundar","year":"2010","unstructured":"Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin\u00a0B for visceral leishmaniasis in India. N Engl J Med. 2010;362:504\u201312.","journal-title":"N Engl J Med"},{"key":"133_CR66","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/clinids\/21.1.188","volume":"21","author":"J Seaman","year":"1995","unstructured":"Seaman J, Boer C, Wilkinson R, et al. Liposomal amphotericin\u00a0B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis. 1995;21:188\u201393.","journal-title":"Clin Infect Dis"},{"key":"133_CR67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trstmh.2006.02.005","volume":"101","author":"M Mueller","year":"2007","unstructured":"Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg. 2007;101:19\u201324.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR68","first-page":"25","volume":"76","author":"JD Berman","year":"1998","unstructured":"Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin\u00a0B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 1998;76:25\u201332.","journal-title":"Bull World Health Organ"},{"issue":"Suppl 2","key":"133_CR69","first-page":"22","volume":"77","author":"H Lagler","year":"2006","unstructured":"Lagler H, Matt U, Sillaber C, Winkler S, Graninger W. Successful treatment of visceral leishmaniasis with liposomal amphotericin\u00a0B. Acta Biomed. 2006;77(Suppl 2):22\u20135.","journal-title":"Acta Biomed"},{"key":"133_CR70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1745-6215-12-66","volume":"12","author":"T Edwards","year":"2011","unstructured":"Edwards T, Omollo R, Khalil EA, et al. Single-dose liposomal amphotericin B (AmBisome\u00ae) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials. 2011;12:66.","journal-title":"Trials"},{"key":"133_CR71","first-page":"75","volume":"87","author":"RN Davidson","year":"1994","unstructured":"Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin\u00a0B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med. 1994;87:75\u201381.","journal-title":"Q J Med"},{"key":"133_CR72","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/clinids\/22.6.938","volume":"22","author":"RN Davidson","year":"1996","unstructured":"Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin\u00a0B (AmBisome). Clin Infect Dis. 1996;22:938\u201343.","journal-title":"Clin Infect Dis"},{"key":"133_CR73","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1086\/367843","volume":"36","author":"V Syriopoulou","year":"2003","unstructured":"Syriopoulou V, Daikos GL, Theodoridou M, et al. Two doses of a lipid formulation of amphotericin\u00a0B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis. 2003;36:560\u20136.","journal-title":"Clin Infect Dis"},{"key":"133_CR74","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1695-4033(03)78776-1","volume":"59","author":"MC Figueras Nadal","year":"2003","unstructured":"Figueras Nadal MC, de Garcia Miguel MJ, Asensi Botet F, Velasco Bernardo R, Canals Baeza A, Ausin Aoiz I. Short course treatment for visceral leishmaniasis with liposomal amphotericin\u00a0B in immunocompetent patients. An Pediatr (Barc). 2003;59:535\u201340.","journal-title":"An Pediatr (Barc)"},{"key":"133_CR75","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.arcped.2005.01.009","volume":"12","author":"P Minodier","year":"2005","unstructured":"Minodier P, Robert S, Noel G, Blanc P, Retornaz K, Garnier JM. First-line liposomal amphotericin\u00a0B for pediatric visceral leishmaniasis in Southern France. Arch Pediatr. 2005;12:1102\u20138.","journal-title":"Arch Pediatr"},{"key":"133_CR76","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijantimicag.2004.09.011","volume":"25","author":"DA Kafetzis","year":"2005","unstructured":"Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G. Treatment of paediatric visceral leishmaniasis: amphotericin\u00a0B or pentavalent antimony compounds? Int J Antimicrob Agents. 2005;25:26\u201330.","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 3","key":"133_CR77","doi-asserted-by":"crossref","first-page":"572s","DOI":"10.1016\/S0929-693X(00)80186-4","volume":"7","author":"P Minodier","year":"2000","unstructured":"Minodier P, Garnier JM. Childhood visceral leishmaniasis in Provence. Arch Pediatr. 2000;7(Suppl 3):572s\u20137s.","journal-title":"Arch Pediatr"},{"key":"133_CR78","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.medmal.2009.05.001","volume":"39","author":"E Rosenthal","year":"2009","unstructured":"Rosenthal E, Delaunay P, Jeandel PY, Haas H, Pomares-Estran C, Marty P. Liposomal amphotericin\u00a0B as treatment for visceral leishmaniasis in Europe, 2009. Med Mal Infect. 2009;39:741\u20134.","journal-title":"Med Mal Infect"},{"key":"133_CR79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1590\/S0036-46652009000400011","volume":"51","author":"ID Velez","year":"2009","unstructured":"Velez ID, Colmenares LM, Munoz CA. Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment. Rev Inst Med Trop Sao Paulo. 2009;51:231\u20136.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"133_CR80","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1365-3156.2008.02128.x","volume":"13","author":"S Sundar","year":"2008","unstructured":"Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M. Safety of a pre-formulated amphotericin\u00a0B lipid emulsion for the treatment of Indian kala-azar. Trop Med Int Health. 2008;13:1208\u201312.","journal-title":"Trop Med Int Health"},{"key":"133_CR81","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4269\/ajtmh.2009.80.700","volume":"80","author":"S Sundar","year":"2009","unstructured":"Sundar S, Singh A, Agarwal D, Rai M, Agrawal N, Chakravarty J. Safety and efficacy of high-dose infusions of a preformed amphotericin\u00a0B fat emulsion for treatment of Indian visceral leishmaniasis. Am J Trop Med Hyg. 2009;80:700\u20133.","journal-title":"Am J Trop Med Hyg"},{"key":"133_CR82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0035-9203(84)90131-7","volume":"78","author":"CP Thakur","year":"1984","unstructured":"Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg. 1984;78:391\u20138.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR83","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/0140-6736(92)92952-C","volume":"340","author":"M Mishra","year":"1992","unstructured":"Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet. 1992;340:1256\u20137.","journal-title":"Lancet"},{"key":"133_CR84","first-page":"117","volume":"5","author":"VN Das","year":"2009","unstructured":"Das VN, Siddiqui NA, Pandey K, et al. A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin\u00a0B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Ther Clin Risk Manag. 2009;5:117\u201324.","journal-title":"Ther Clin Risk Manag"},{"key":"133_CR85","first-page":"609","volume":"49","author":"VN Das","year":"2001","unstructured":"Das VN, Ranjan A, Sinha AN, et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Phys India. 2001;49:609\u201313.","journal-title":"J Assoc Phys India"},{"key":"133_CR86","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4269\/ajtmh.1991.45.435","volume":"45","author":"CP Thakur","year":"1991","unstructured":"Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg. 1991;45:435\u201341.","journal-title":"Am J Trop Med Hyg"},{"key":"133_CR87","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/00034989859988","volume":"92","author":"EA Khalil","year":"1998","unstructured":"Khalil EA, el Hassan AM, Zijlstra EE, et al. Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. Ann Trop Med Parasitol. 1998;92:151\u20138.","journal-title":"Ann Trop Med Parasitol"},{"key":"133_CR88","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.316.7139.1200","volume":"316","author":"TK Jha","year":"1998","unstructured":"Jha TK, Olliaro P, Thakur CP, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in north Bihar, India. BMJ. 1998;316:1200\u20135.","journal-title":"BMJ"},{"key":"133_CR89","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","volume":"356","author":"S Sundar","year":"2007","unstructured":"Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356:2571\u201381.","journal-title":"N Engl J Med"},{"key":"133_CR90","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1086\/605438","volume":"49","author":"S Sundar","year":"2009","unstructured":"Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin Infect Dis. 2009;49:914\u20138.","journal-title":"Clin Infect Dis"},{"key":"133_CR91","doi-asserted-by":"crossref","first-page":"645203","DOI":"10.1155\/2011\/645203","volume":"2011","author":"PK Sinha","year":"2011","unstructured":"Sinha PK, Jha TK, Thakur CP, et al. Phase\u00a04 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. J Trop Med. 2011;2011:645203.","journal-title":"J Trop Med"},{"key":"133_CR92","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0035-9203(90)90263-E","volume":"84","author":"CN Chunge","year":"1990","unstructured":"Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg. 1990;84:221\u20135.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4269\/ajtmh.2007.77.89","volume":"77","author":"Y Melaku","year":"2007","unstructured":"Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN. Treatment of kala-azar in Southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg. 2007;77:89\u201394.","journal-title":"Am J Trop Med Hyg"},{"key":"133_CR94","doi-asserted-by":"crossref","first-page":"e709","DOI":"10.1371\/journal.pntd.0000709","volume":"4","author":"A Hailu","year":"2010","unstructured":"Hailu A, Musa A, Wasunna M, et al. Geographical variation in the response of visceral leishmaniasis to paromomycin in east Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis. 2010;4:e709.","journal-title":"PLoS Negl Trop Dis"},{"key":"133_CR95","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1371\/journal.pntd.0000855","volume":"4","author":"AM Musa","year":"2010","unstructured":"Musa AM, Younis B, Fadlalla A, et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis. 2010;4:e855.","journal-title":"PLoS Negl Trop Dis"},{"key":"133_CR96","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0035-9203(00)90130-5","volume":"94","author":"CP Thakur","year":"2000","unstructured":"Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2000;94:429\u201331.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR97","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0035-9203(92)90150-B","volume":"86","author":"CP Thakur","year":"1992","unstructured":"Thakur CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (=\u00a0paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg. 1992;86:615\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR98","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","volume":"47","author":"S Sundar","year":"2008","unstructured":"Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin\u00a0B followed by short-course oral miltefosine. Clin Infect Dis. 2008;47:1000\u20136.","journal-title":"Clin Infect Dis"},{"key":"133_CR99","doi-asserted-by":"crossref","unstructured":"Sundar S, Sinha PK, Rai M, et\u00a0al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377:477\u201386.","DOI":"10.1016\/S0140-6736(10)62050-8"},{"key":"133_CR100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trstmh.2010.10.008","volume":"105","author":"S Sundar","year":"2011","unstructured":"Sundar S, Sinha PK, Verma DK, et al. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2011;105:115\u20137.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR101","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","volume":"6","author":"A Musa","year":"2012","unstructured":"Musa A, Khalil E, Hailu A, et al. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in east Africa: a randomised controlled trial. PLoS Negl Trop Dis. 2012;6:e1674.","journal-title":"PLoS Negl Trop Dis"},{"key":"133_CR102","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1745-6215-12-166","volume":"12","author":"R Omollo","year":"2011","unstructured":"Omollo R, Alexander N, Edwards T, et al. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin\u00a0B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials. 2011;12:166.","journal-title":"Trials"},{"key":"133_CR103","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1086\/425359","volume":"39","author":"H Sindermann","year":"2004","unstructured":"Sindermann H, Engel KR, Fischer C, Bommer W, Miltefosine Compassionate Use Program. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis. 2004;39:1520\u20133.","journal-title":"Clin Infect Dis"},{"key":"133_CR104","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/00365540701466215","volume":"40","author":"J Troya","year":"2008","unstructured":"Troya J, Casquero A, Refoyo E, Fernandez-Guerrero ML, Gorgolas M. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis. 2008;40:78\u201380.","journal-title":"Scand J Infect Dis"},{"key":"133_CR105","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/01.aids.0000226971.42622.4e","volume":"20","author":"NS Redhu","year":"2006","unstructured":"Redhu NS, Dey A, Balooni V, Singh S. Leishmania-HIV co-infection: an emerging problem in India. AIDS. 2006;20:1213\u20135.","journal-title":"AIDS"},{"key":"133_CR106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00126334-200301010-00017","volume":"32","author":"PK Sinha","year":"2003","unstructured":"Sinha PK, Rabidas VN, Pandey K, et al. Visceral leishmaniasis and HIV co-infection in Bihar, India. J Acquir Immune Defic Syndr. 2003;32:115\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"133_CR107","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1198-743x.2001.00262.x","volume":"7","author":"V Pintado","year":"2001","unstructured":"Pintado V, Lopez-Velez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect. 2001;7:291\u2013300.","journal-title":"Clin Microbiol Infect"},{"key":"133_CR108","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/00002030-199906180-00009","volume":"13","author":"F Laguna","year":"1999","unstructured":"Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin\u00a0B. Spanish HIV-Leishmania Study Group. AIDS. 1999;13:1063\u20139.","journal-title":"AIDS"},{"key":"133_CR109","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","volume":"52","author":"F Laguna","year":"2003","unstructured":"Laguna F, Videla S, Jimenez-Mejias ME, et al. Amphotericin\u00a0B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother. 2003;52:464\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"133_CR110","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0035-9203(01)90110-5","volume":"95","author":"K Ritmeijer","year":"2001","unstructured":"Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg. 2001;95:668\u201372.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"133_CR111","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1016\/j.ijid.2009.06.010","volume":"14","author":"J Rybniker","year":"2010","unstructured":"Rybniker J, Goede V, Mertens J, et al. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure\u2014a case report and brief review of the literature. Int J Infect Dis. 2010;14:e522\u20135.","journal-title":"Int J Infect Dis"},{"key":"133_CR112","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1093\/cid\/cir674","volume":"53","author":"K Ritmeijer","year":"2011","unstructured":"Ritmeijer K, ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin\u00a0B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis. 2011;53:e152\u20138.","journal-title":"Clin Infect Dis"},{"key":"133_CR113","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/cid\/cir521","volume":"53","author":"PK Sinha","year":"2011","unstructured":"Sinha PK, van Griensven J, Pandey K, et al. Liposomal amphotericin\u00a0B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis. 2011;53:e91\u20138.","journal-title":"Clin Infect Dis"},{"key":"133_CR114","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0163-4453(94)91643-8","volume":"28","author":"F Laguna","year":"1994","unstructured":"Laguna F, Lopez-Velez R, Soriano V, Montilla P, Alvar J, Gonzalez-Lahoz JM. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect. 1994;28:255\u20139.","journal-title":"J Infect"},{"key":"133_CR115","first-page":"197","volume":"12","author":"A Mastroianni","year":"2004","unstructured":"Mastroianni A. Liposomal amphotericin\u00a0B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS. Infez Med. 2004;12:197\u2013204.","journal-title":"Infez Med"},{"key":"133_CR116","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jac\/dkh084","volume":"53","author":"R Lopez-Velez","year":"2004","unstructured":"Lopez-Velez R, Videla S, Marquez M, et al. Amphotericin\u00a0B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother. 2004;53:540\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"133_CR117","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/dkm294","volume":"60","author":"I Molina","year":"2007","unstructured":"Molina I, Falco V, Crespo M, et al. Efficacy of liposomal amphotericin\u00a0B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother. 2007;60:837\u201342.","journal-title":"J Antimicrob Chemother"},{"key":"133_CR118","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0002-9343(97)89503-4","volume":"100","author":"E Ribera","year":"1996","unstructured":"Ribera E, Ocana I, de Otero J, Cortes E, Gasser I, Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med. 1996;100:496\u2013501.","journal-title":"Am J Med"},{"key":"133_CR119","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4269\/ajtmh.1998.58.436","volume":"58","author":"R Lopez-Velez","year":"1998","unstructured":"Lopez-Velez R, Perez-Molina JA, Guerrero A, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients co-infected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg. 1998;58:436\u201343.","journal-title":"Am J Trop Med Hyg"},{"key":"133_CR120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00002030-199602000-00023","volume":"10","author":"JA Perez-Molina","year":"1996","unstructured":"Perez-Molina JA, Lopez-Velez R, Montilla P, Guerrero A. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS. 1996;10:237\u20138.","journal-title":"AIDS"},{"key":"133_CR121","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/00365540701787800","volume":"40","author":"N Marques","year":"2008","unstructured":"Marques N, Sa R, Coelho F, Oliveira J, Saraiva Da Cunha J, Melico-Silvestre A. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. Scand J Infect Dis. 2008;40:523\u20136.","journal-title":"Scand J Infect Dis"},{"key":"133_CR122","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF01709465","volume":"17","author":"G Angarano","year":"1998","unstructured":"Angarano G, Maggi P, Coppola SL, Cavaliere RL. Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1998;17:365\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"133_CR123","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0002-9343(92)90281-F","volume":"92","author":"A Lafeuillade","year":"1992","unstructured":"Lafeuillade A, Chaffanjon P, Delbeke E, Quilichini R. Maintenance itraconazole for visceral leishmaniasis in HIV infection. Am J Med. 1992;92:449.","journal-title":"Am J Med"},{"key":"133_CR124","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/clinids\/21.5.1338","volume":"21","author":"F Raffi","year":"1995","unstructured":"Raffi F, Merrien D, Le Pape P, Reliquet V. Use of an Itraconazole\/allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. Clin Infect Dis. 1995;21:1338\u20139.","journal-title":"Clin Infect Dis"},{"key":"133_CR125","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1097\/00002030-200012220-00020","volume":"14","author":"J Berenguer","year":"2000","unstructured":"Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS. 2000;14:2946\u20138.","journal-title":"AIDS"},{"key":"133_CR126","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00002030-200003100-00011","volume":"14","author":"VF Soriano","year":"2000","unstructured":"Soriano VF, Dona CF, Rodriguez-Rosado RF, Barreiro PF, Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2000;14:383\u20136.","journal-title":"AIDS"},{"key":"133_CR127","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","volume":"352","author":"S Sundar","year":"1998","unstructured":"Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 1998;352:1821\u20133.","journal-title":"Lancet"},{"key":"133_CR128","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","volume":"341","author":"TK Jha","year":"1999","unstructured":"Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med. 1999;341:1795\u2013800.","journal-title":"N Engl J Med"},{"key":"133_CR129","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","volume":"347","author":"S Sundar","year":"2002","unstructured":"Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739\u201346.","journal-title":"N Engl J Med"},{"key":"133_CR130","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","volume":"196","author":"SK Bhattacharya","year":"2007","unstructured":"Bhattacharya SK, Sinha PK, Sundar S, et al. Phase\u00a04 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis. 2007;196:591\u20138.","journal-title":"J Infect Dis"},{"key":"133_CR131","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/0140-6736(91)90268-T","volume":"337","author":"M Mishra","year":"1991","unstructured":"Mishra M, Singh MP, Choudhury D, Singh VP, Khan AB. Amphotericin\u00a0B for second-line treatment of Indian kala-azar. Lancet. 1991;337:926.","journal-title":"Lancet"},{"key":"133_CR132","first-page":"170","volume":"97","author":"CP Thakur","year":"1993","unstructured":"Thakur CP, Sinha GP, Sharma V, Pandey AK, Kumar M, Verma BB. Evaluation of amphotericin\u00a0B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian J Med Res. 1993;97:170\u20135.","journal-title":"Indian J Med Res"},{"key":"133_CR133","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/00034983.1994.11812878","volume":"88","author":"CP Thakur","year":"1994","unstructured":"Thakur CP, Sinha GP, Barat D, Singh RK. Are incremental doses of amphotericin\u00a0B required for the treatment of visceral leishmaniasis? Ann Trop Med Parasitol. 1994;88:365\u201370.","journal-title":"Ann Trop Med Parasitol"},{"key":"133_CR134","first-page":"688","volume":"42","author":"OP Giri","year":"1994","unstructured":"Giri OP. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B. J Assoc Phys India. 1994;42:688\u20139.","journal-title":"J Assoc Phys India"},{"key":"133_CR135","first-page":"690","volume":"42","author":"OP Giri","year":"1994","unstructured":"Giri OP, Singh AN. Experience with amphotericin\u00a0B in sodium stibogluconate\u2014unresponsive cases of visceral leishmaniasis in North Bihar. J Assoc Phys India. 1994;42:690\u20131.","journal-title":"J Assoc Phys India"},{"key":"133_CR136","first-page":"259","volume":"103","author":"CP Thakur","year":"1996","unstructured":"Thakur CP, Sinha GP, Pandey AK. Comparison of regimens of amphotericin\u00a0B deoxycholate in kala-azar. Indian J Med Res. 1996;103:259\u201363.","journal-title":"Indian J Med Res"},{"key":"133_CR137","first-page":"779","volume":"46","author":"CP Thakur","year":"1998","unstructured":"Thakur CP, Kumar P, Kumar N, Singh GN, Singh AK, Narain S. A randomized comparison of classical mode of administration of amphotericin\u00a0B with its newer modes of administration in kala-azar. J Assoc Phys India. 1998;46:779\u201383.","journal-title":"J Assoc Phys India"},{"key":"133_CR138","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0035-9203(99)90037-8","volume":"93","author":"CP Thakur","year":"1999","unstructured":"Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin\u00a0B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg. 1999;93:319\u201323.","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0133-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0133-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0133-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T08:31:43Z","timestamp":1564561903000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0133-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,30]]},"references-count":138,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0133-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,30]]}}}